A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy

Maturitas

Volumn 39, Issue 3, 2001, Pages 217-225

  Marttunen, Merja B ^a   Hietanen, Päivi ^a   Pyrhönen, Seppo ^a   Tiitinen, Aila ^a   Ylikorkala, Olavi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Breast cancer; Contralateral; Estrogen replacement therapy

Indexed keywords

ESTRADIOL; ESTRADIOL VALERATE; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; BLEEDING DISORDER; BREAST CARCINOMA; BREAST EXAMINATION; CANCER RECURRENCE; CANCER RISK; CLIMACTERIUM; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; ILLNESS BEHAVIOR; MAJOR CLINICAL STUDY; METASTASIS; OUTPATIENT DEPARTMENT; POSTMENOPAUSE; SPOTTING; THICKNESS; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FINLAND; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 0035964844     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(01)00211-0     Document Type: Article

References (31)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
2. Relation of tumour size, lymph node status, and survival in 24740 breast cancer cases
3. Late mortality from pT1N0M0 breast cancer
4. Increasing incidence of and declining mortality from breast carcinoma: Trends in Malmö, Sweden, 1961-1992
5. 16-Year mortality from breast cancer in UK Trial of Early Detection of Breast Cancer
6. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer
7. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer
8. The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long-term tissue culture
9. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
10. Hormone replacement therapy and malignancy
11. Supplemental estrogen replacement
12. Oestrogen replacement therapy for breast cancer patients
13. Reduced mortality associated with long-term postmenopausal oestrogen therapy
14. Hormone replacement therapy in a risk-benefit perspective
15. Oestrogen replacement therapy in breast cancer survivors
16. Hormone replacement therapy in women with breast cancer: Do the risks outweigh the benefits?
17. Hormone replacement therapy in women with breast cancer
18. Hormone replacement therapy in previously treated breast cancer patients
19. Hormone replacement after breast cancer
20. Hormone replacement therapy in breast cancer
21. A case-control study of combined continuous oestrogen-progestin replacement therapy among women with a personal history of breast cancer
22. Oestrogen replacement therapy in women with prior diagnosis and treatment for breast cancer
23. Estrogen replacement therapy in women with previous breast cancer
24. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment
25. A cohort study of hormone replacement therapy given to women previously treated for breast cancer
26. Risk for endometrial cancer following breast cancer: A prospective study in Sweden
27. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement therapy
28. Menopausal estrogen and estrogen-progestin replacement therapy and beast cancer risk
29. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen-progestin
30. Strategies to reduce the incidence of endometrial cancer in postmenopausal women
31. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial